# Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

> **NCT00870844** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 24 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Lu AA24493 (CEPO)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00870844
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00870844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00870844, "Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00870844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*